FDA OKs New Once-Daily Asthma Treatment – WebMD


Bidness Etc

FDA OKs New Once-Daily Asthma Treatment
WebMD
Arnuity Ellipta has been tested in more than 3,600 people with asthma, the company says in a statement. The most common side effects (reported in at least 5% of people) were upper respiratory tract infection, common cold, headache, and bronchitis.
GlaxoSmithKline grabs FDA approval for its latest asthma treatmentFierceBiotech
GSK's Asthma Treatment Gets FDA ApprovalBidness Etc
FDA OKs New Maintenance Asthma Treatment Arnuity ElliptaMedscape
Philadelphia Business Journal (blog) –Pharmaceutical Business Review –Healio
all 29 news articles »

View full post on asthma – Google News

FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma – News-Medical.net

FDA approves GlaxoSmithKline's Arnuity Ellipta for treatment of asthma
News-Medical.net
GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 …

View full post on asthma – Google News

GlaxoSmithKline grabs FDA approval for its latest asthma treatment – FierceBiotech


Bidness Etc

GlaxoSmithKline grabs FDA approval for its latest asthma treatment
FierceBiotech
"The approval of Arnuity Ellipta is an important development for GSK and our expanding respiratory portfolio," Senior Vice President Darrell Baker said in a statement. "It is the first asthma treatment from our new portfolio to have gained approval in
GSK's Asthma Treatment Gets FDA ApprovalBidness Etc
FDA OKs New Maintenance Asthma Treatment Arnuity ElliptaMedscape
FDA approves GSK asthma medicinePhiladelphia Business Journal (blog)
Healio –Monthly Prescribing Reference –The Pharma Letter
all 24 news articles »

View full post on asthma – Google News

GSK’s Asthma Treatment Gets FDA Approval – Bidness Etc


Bidness Etc

GSK's Asthma Treatment Gets FDA Approval
Bidness Etc
Yesterday, GlaxoSmithKline plc (GSK) announced that the Food and Drug Administration (FDA) has given marketing approval for its drug Arnuity Ellipta, developed as an asthma treatment in patients aged 12 and older. Asthma is a lingering lung disease
FDA OKs New Maintenance Asthma Treatment Arnuity ElliptaMedscape
FDA approves GSK asthma medicinePhiladelphia Business Journal (blog)
FDA approves GSK's Arnuity Ellipta for treating asthmaHealio
Monthly Prescribing Reference –News-Medical.net –The Pharma Letter
all 21 news articles »

View full post on asthma – Google News

Malaria Drugs Eyed As Asthma Treatment, Liver Cancer Prevention Tactic – Pharmaceutical Online (press release)


TheHealthSite

Malaria Drugs Eyed As Asthma Treatment, Liver Cancer Prevention Tactic
Pharmaceutical Online (press release)
Researchers from the National University of Singapore (NUS) recently discovered that two, traditional anti-malaria drugs could be used to treat asthma and prevent liver cancer. Artesunate for injection is manufactured by Guilin Pharmaceuticals and
Artesunate drug can be used to control asthma, finds NUS studyNews-Medical.net
Herbal-Based Anti-Malarial Drug Artesunate Also Helps Control Asthma – StudyScience 2.0
Herbal anti-malaria drug may help in controlling asthmaTheHealthSite
Zee News
all 24 news articles »

View full post on asthma – Google News

A Computational Physiology Approach to Personalized Treatment Models: The Beneficial Effects of Slow Breathing on the Human Cardiovascular System.

A Computational Physiology Approach to Personalized Treatment Models: The Beneficial Effects of Slow Breathing on the Human Cardiovascular System.

Am J Physiol Heart Circ Physiol. 2014 Jul 25;

Authors: Fonoberova M, Mezic I, Buckman JF, Fonoberov VA, Mezic A, Vaschillo E, Mun EY, Vaschillo B, Bates ME

Abstract
Heart rate variability biofeedback intervention involves slow breathing at a rate of ~6 breaths per min (resonance breathing) to maximize respiratory and baroreflex effects on heart period oscillations. This intervention has wide-ranging clinical benefits and is gaining empirical support as an adjunct therapy for biobehavioral disorders, including asthma and depression. Yet, little is known about the system-level cardiovascular changes that occur during resonance breathing or the extent to which individuals differ in cardiovascular benefit. This study used a computational physiology approach to dynamically model the human cardiovascular system at rest and during resonance breathing. Noninvasive measurements of heart period, beat-to-beat systolic and diastolic blood pressure, and respiration period were obtained from 24 healthy young men and women. A model with respiration as input was parameterized to better understand how the cardiovascular processes that control variability in heart period and blood pressure change from rest to resonance breathing. The cost function used in model calibration corresponded to the difference between the experimental data and model outputs. A good match was observed between the data and model outputs (heart period, blood pressure, and corresponding power spectral densities). Significant improvements in several modeled cardiovascular functions (e.g., blood flow to internal organs, sensitivity of the sympathetic component of the baroreflex, ventricular elastance) were observed during resonance breathing. Individual differences in the magnitude and nature of these dynamic responses suggest that computational physiology may be clinically useful for tailoring heart rate variability biofeedback interventions for the needs of individual patients.

PMID: 25063789 [PubMed – as supplied by publisher]

View full post on pubmed: asthma